Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$7.86 USD
-0.14 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.88 +0.02 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.86 USD
-0.14 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.88 +0.02 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
by Zacks Equity Research
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
by Zacks Equity Research
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
by Zacks Equity Research
Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 51.61% and 29.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
by Zacks Equity Research
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
by Zacks Equity Research
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?